Starpharma Holdings Limited
3.50
USD
-1.70
(-32.69%)
ISIN
US8555631022
CUSIP
855563102
Return %
Stock
S&P 500
1Y
100.00
14.20
3Y
354.55
81.12
5Y
-58.82
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Cheryl Maley
- Full Time Employees
- 50
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 4-6 Southampton Crescent Abbotsford VIC Australia 3067
- IPO Date
- Aug 28, 2000
- Website
- starpharma.com
- Similar Companies
- Business
- Starpharma Holdings Limited (SPL.AX) develops and commercializes dendrimer nanotechnology platforms for applications in pharmaceuticals, antiviral treatments, and agricultural technologies. The company offers core products and services including VivaGel, a non-hormonal vaginal microbicide for bacterial vaginosis treatment; dendrimer-based antiviral gels and coatings for preventing HIV, herpes, and influenza transmission; and targeted drug delivery systems using Priostar dendrimers for oncology and other therapeutics; as well as agricultural solutions like AgroStar dendrimers for enhanced crop protection and delivery of active ingredients. Starpharma operates primarily in the biotechnology and nanotechnology sectors, targeting pharmaceutical companies, healthcare providers, and agribusinesses across Australia, the United States, Europe, and Asia-Pacific regions. Founded in 1996 and headquartered in Melbourne, Australia, the company maintains strategic partnerships with global firms such as GSK and Janssen for product development and commercialization, with no major subsidiaries or parent relationships publicly noted. In recent developments within the last two years, Starpharma expanded its antiviral portfolio through clinical advancements in dendrimer nasal sprays for COVID-19 prevention and secured new licensing agreements for VivaGel in additional international markets, alongside ongoing funding from government grants and investor rounds to support Phase III trials and manufacturing scale-up.
Company News
Starpharma (OTCMKTS:SPHRY) Stock Price Down 13.7% – Time to Sell?
Edison Issues Report on Starpharma (SPL)
US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments
Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma
Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack
Starpharma Up With News, Down With None; Timing Entry Makes Sense
Starpharma signs DEP® ADC Research Agreement with MSD
Starpharma Viraleze: COVID-19 Nasal Spray Development